Physician profile
Kenneth Oghale Osiezagha
NPI 1205181724
$15,603.65
in general payments reported to CMS, 2019-2025
31 companies · $2,406 in 2025
The $2,406 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $150 · 2021: $433 · 2022: $1,356 · 2023: $2,185 · 2024: $8,773 · 2025: $2,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,758 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,460 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,758.29 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,460.00 |
| Education | $145.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $6,879.40 | 2023-2025 | Loreev Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,690.63 | 2022-2025 | Caplyta |
| Abbvie INC. | $1,220.63 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $873.13 | 2019-2025 | Trintellix |
| Lundbeck LLC | $668.47 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $660.12 | 2019-2025 | Rexulti, Abilify Mycite, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $547.21 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $526.39 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $437.66 | 2019-2025 | Aristada, Lybalvi |
| Corium, LLC | $335.06 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $321.36 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $245.57 | 2021-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $233.10 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $153.61 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Tris Pharma INC | $148.02 | 2022-2025 | Dyanavel Xr |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $117.77 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $98.94 | 2024-2025 | Cobenfy |
| Eisai INC. | $63.54 | 2021-2022 | |
| Lilly USA, LLC | $63.24 | 2022-2025 | Zepbound, Mounjaro |
| Indivior INC. | $62.76 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $58.96 | 2019-2025 | Ingrezza |
| Tempus Ai, INC | $36.26 | 2024 | Tempus Pixel |
| Idorsia Pharmaceuticals US INC | $33.05 | 2023 | Quviviq |
| Nevro Corp. | $21.85 | 2020 | |
| Brainsway USA INC | $18.72 | 2025 | Deep Tms System |
| Merck Sharp & Dohme LLC | $17.75 | 2019 | |
| Adlon Therapeutics L.P. | $16.37 | 2021 | |
| Jazz Pharmaceuticals INC. | $15.00 | 2019 | |
| Neos Therapeutics, Lp | $14.05 | 2020 | |
| Mylan Specialty L.P. | $13.01 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Osiezagha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.